SCHEMBL5714928

SCHEMBL5714928

Cc1cccc(CCc2ccc(OC(=O)N3CCN(c4ccc(CC(=O)O)cn4)CC3)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 5/20 0.45
PANK3 Q9H999 1/20 0.43
ME2 P23368 5/20 0.42
ME1 P48163 5/20 0.42
ME3 Q16798 5/20 0.42
WNT3A P56704 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
PTGDR2 Q9Y5Y4 3/20 0.39
HPGD P15428 2/20 0.39
GPR119 Q8TDV5 1/20 0.39
SMO Q99835 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714825 0.92 PANK3 (0.46) AOC3PANK3ME2ME1ME3
SCHEMBL5713910 0.90 PANK3 (0.45) AOC3PANK3ME2ME1ME3
SCHEMBL5715236 0.89 HRH3 (0.43) AOC3PANK3ME2ME1ME3
SCHEMBL5715861 0.88 PANK3 (0.46) AOC3PANK3ME2ME1ME3
SCHEMBL5715191 0.88 ME2 (0.45) AOC3PANK3ME2ME1ME3
SCHEMBL5714546 0.86 SMN1; SMN2 (0.58) SMN1; SMN2HSD17B10KDM4EALDH1A1LMNA
SCHEMBL5714287 0.86 AOC3 (0.44) AOC3PANK3HSD17B10RAB9AHPGD
SCHEMBL5714583 0.85 AOC3 (0.47) AOC3PANK3ME2ME1ME3
SCHEMBL5715523 0.85 HSD17B10 (0.52) SMN1; SMN2HSD17B10KDM4EALDH1A1LMNA
SCHEMBL5715073 0.84 PANK3 (0.43) AOC3PANK3ME2ME1ME3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC AOC3 2256/4885PANK3 1247/4885ME2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.